Financhill
Back

WuXi Biologics (Cayman) Quote, Financials, Valuation and Earnings

WuXi Biologics (Cayman) Price Quote

$2.50

WuXi Biologics (Cayman) Key Stats

Buy
78
WuXi Biologics (Cayman) (WXIBF) is a Buy

Day range:
$2.50 - $2.50
52-week range:
$1.30 - $3.92
Dividend yield:
0%
P/E ratio:
22.97
P/S ratio:
4.52
P/B ratio:
1.84%

Volume:
0
Avg. volume:
402
1-year change:
-28.57%
Market cap:
$10.3B
Revenue:
$2.4B
EPS:
$0.08

How Much Does WuXi Biologics (Cayman) Make?

Is WuXi Biologics (Cayman) Growing As A Company?

Data Unavailable

WuXi Biologics (Cayman) Stock Price Performance

What Is WuXi Biologics (Cayman) 52-Week High & Low?

WuXi Biologics (Cayman) Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy WuXi Biologics (Cayman)?

Is WuXi Biologics (Cayman) Cash Flow Positive?

  • What Is WXIBF Cash Flow From Operations?
    Cash flow from operations (TTM) is $447.4M
  • What Is WuXi Biologics (Cayman)’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $93.4M
  • What Is WuXi Biologics (Cayman)’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$280.9M

WuXi Biologics (Cayman) Return On Invested Capital

  • Is Management Doing A Good Job?
    WXIBF return on invested capital is 5.86%
  • What Is WuXi Biologics (Cayman) Return On Assets?
    ROA measures how assets are converting to revenues and is 4.8%
  • What Is WXIBF Return On Equity?
    ROE is a measure of profitability and is 6.19%

WuXi Biologics (Cayman) Earnings Date & Stock Price

WuXi Biologics (Cayman) Competitors

WuXi Biologics (Cayman) Dividend Yield

WuXi Biologics (Cayman) Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 0%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 0
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 0.00
Downside from Last Price: -100%

Major Shareholders

  • How many WXIBF shares are owned by institutional investors?
    1.3B WXIBF shares are owned by institutional investors
  • How many WXIBF shares are owned by insiders?
    0 WXIBF shares are owned by insiders